Eli Lilly gets a date with FDA experts for once-rejected rheumatoid arthritis drug baricitinib
Eli Lilly’s one-time blockbuster hopeful baricitinib $LLY is back and on track and ready to run a gamut of outside experts at the FDA.
The agency is calling a session of its arthritis advisory committee on April 23rd to weigh in on Lilly’s application, which was given a stunning rejection for safety issues last year that derailed the pharma giant’s earlier promise of scoring two new drug approvals a year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
